Cullinan Therapeutics CGEM
NASDAQ CGEM
$22.17 +0.01 (+0.05%)
As of: Sep 4, 2026 · 2:30 PM EDT

Cullinan Therapeutics (CGEM) EV to EBITDA (2021 - 2026)

Analysis

Cullinan Therapeutics (CGEM) EV to EBITDA (2021 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.78 Bn 130.92 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.50 Bn 77.51 Bn 3.93 Bn
3 Argenx Se 63.51 Bn 58.32 Bn 1.37 Bn
4 Moderna 58.06 Bn 52.92 Bn 52.00 Mn
5 Revolution Medicines 44.04 Bn 44.04 Bn -
6 BeOne Medicines 40.04 Bn 34.94 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.45 Bn 32.14 Bn 992.69 Mn
8 Royalty Pharma 28.41 Bn 27.57 Bn -
9 Insmed 27.42 Bn 26.26 Bn 358.27 Mn
10 Cullinan Therapeutics 1.37 Bn 1.37 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -10.15
Mar 31, 2026 -4.55
Dec 31, 2025 -4.45
Sep 30, 2025 3.80
Jun 30, 2025 0.18
Mar 31, 2025 1.58
Dec 31, 2024 -5.70
Sep 30, 2024 1.65
Jun 30, 2024 -6.93
Mar 31, 2024 -7.00
Dec 31, 2023 0.65
Sep 30, 2023 10.63
Jun 30, 2023 10.16
Mar 31, 2023 4.09
Dec 31, 2022 -0.49
Sep 30, 2022 10.85
Jun 30, 2022 -1.19
Mar 31, 2022 2.61
Dec 31, 2021 -11.45
Sep 30, 2021 -16.83